Founded in Broomfield, Colorado, Colorado Therapeutics specializes in developing xenogenic tissue matrix products aimed at soft tissue reinforcement and regeneration. The company's core mission is to advance medical technology through innovative biologic implants that enhance tissue repair and regenerative processes. Their flagship product, XI-S+™, is a lightweight biologic implant designed for a variety of soft tissue and vascular applications, targeting both the medical and surgical markets.
Notable affiliations include a license agreement with Micro Interventional Devices for the use of PolyCor™ Anchoring Technology. Colorado Therapeutics has achieved significant milestones in research and development, positioning itself as a leader in the biologic implant sector. The company's impact is marked by its contributions to improving patient outcomes in soft tissue repair and regenerative medicine.
